MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 886 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MRTX849 acid
CAS:<p>MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.</p>Fórmula:C34H37ClFN7O4Cor e Forma:SolidPeso molecular:662.16KRAS inhibitor-34
CAS:<p>KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.</p>Fórmula:C43H41F3N6O3Cor e Forma:SolidPeso molecular:746.82KRASG12C IN-13
CAS:<p>KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.</p>Fórmula:C22H17ClF2N6OSCor e Forma:SolidPeso molecular:486.93KRAS G12D inhibitor 11
CAS:<p>KRAS G12D inhibitor 11 targets KRAS G12D in cancer research (patent WO2021108683A1, compound 52).</p>Fórmula:C29H38BN5O3Cor e Forma:SolidPeso molecular:515.4510-Methoxy-canthin-6-one
CAS:<p>10-Methoxy-canthin-6-one (Mtx-C) acts as a DNA damage inducer that embeds into DNA, promoting cell cycle arrest at the G2/M phase. This process triggers myeloid differentiation in acute myeloid leukemia cells (AML) and leukemia stem cells (LSC). Differentiation in AML and LSC cells is characterized by increased expression of myeloperoxidase, CD15, CD11b, and CD14, along with the activation of p38 MAPK. 10-Methoxy-canthin-6-one is utilized in the study of leukemia.</p>Fórmula:C15H10N2O2Cor e Forma:SolidPeso molecular:250.25KRAS G12C inhibitor 33
CAS:<p>KRAS G12C inhibitor 33 is a KRAS G12C inhibitor that can be used to study cancer.</p>Fórmula:C30H33N7O3Cor e Forma:SolidPeso molecular:539.63Refametinib R enantiomer
CAS:<p>Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used</p>Fórmula:C19H20F3IN2O5SPureza:99.86%Cor e Forma:SolidPeso molecular:572.34KRAS G12D inhibitor 9
CAS:<p>KRAS G12D inhibitor 9 targets RAS protein, key in growth, showing promise against KRAS G12D cancer.</p>Fórmula:C33H43N7O2Cor e Forma:SolidPeso molecular:569.74JNK-1-IN-4
CAS:<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>Fórmula:C22H25BrN6O3Cor e Forma:SolidPeso molecular:501.38LZTR1-KRAS modulator 1
CAS:<p>LZTR1-KRAS modulator 1 is a regulator of the KRAS-LZTR1 interaction, enhancing the recruitment of the LZTR1-KRAS complex.</p>Fórmula:C11H11Cl2NOCor e Forma:SolidPeso molecular:244.12KRAS inhibitor-32
CAS:<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Fórmula:C29H35FN10OS2Cor e Forma:SolidPeso molecular:622.78Anti-osteoporosis agent-11
CAS:<p>Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.</p>Fórmula:C23H17NO2Se2Cor e Forma:SolidPeso molecular:497.31NDI-101150
CAS:<p>NDI-101150 (NMBS-2) is an HPK1 inhibitor with antitumor activity, inhibiting BLNK phosphorylation, and used in metastatic solid tumor research.</p>Fórmula:C27H27FN6O2Pureza:99.65%Cor e Forma:SolidPeso molecular:486.54INS018 055
CAS:<p>INS018 055 (TNIK&amp;MAP4K4-IN-2) is a TNIK and MAP4K4 inhibitor with anti-fibrotic activity.</p>Fórmula:C27H30FN7OPureza:98.53%Cor e Forma:SolidPeso molecular:487.57Emprumapimod
CAS:<p>Emprumapimod, an oral p38α MAPK inhibitor, targets RPMI-8226 cells, curbs LPS-induced IL-6; IC50: 100 pM; for cardiomyopathy, acute pain.</p>Fórmula:C24H29F2N5O3Pureza:99.21% - >99.99%Cor e Forma:SolidPeso molecular:473.52Rineterkib
CAS:<p>Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.</p>Fórmula:C26H27BrF3N5O2Pureza:99.73%Cor e Forma:SolidPeso molecular:578.42CMK
CAS:<p>CMK, an RSK2 kinase inhibitor, shows similar potency but less chemical stability compared with FMK.</p>Fórmula:C18H19ClN4O2Cor e Forma:SolidPeso molecular:358.82Ravoxertinib hydrochloride
CAS:<p>Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).</p>Fórmula:C21H19Cl2FN6O2Pureza:98%Cor e Forma:SolidPeso molecular:477.32Omtriptolide
CAS:<p>Omtriptolide, triptolide purified from the Chinese herb, is a water-soluble derivative prodrug.</p>Fórmula:C24H28O9Pureza:98%Cor e Forma:SolidPeso molecular:460.479PLX7922
CAS:<p>PLX7922, a RAF inhibitor, demonstrates binding affinity with BRAF V600E and exhibits inhibitory effects on pERK in BRAF V600E cell lines, while inducing pERK activation in mutant NRAS cell lines.</p>Fórmula:C20H25FN6O2S2Cor e Forma:SolidPeso molecular:464.58
